Europe Microbiology Testing/Clinical Microbiology Market

Europe Microbiology Testing Market Size (2023 to 2028)

The size of the Europe microbiology testing/clinical microbiology market is expected to be worth USD 2.43 billion by 2028 from USD 1.36 billion in 2023, growing at a CAGR of 12.2% from 2023 to 2028.

Technology advancements in disease diagnostics across Europe are majorly driving the European market growth. Various advanced molecular diagnostic techniques are widely used to detect and effectively treat pathogen-borne diseases. Compared to traditional lab techniques, advanced molecular techniques offer various technical benefits such as high sample detection, specificity, accuracy, increased device sensitivity, and rapid results. Several techniques, such as real-time PCR, NGS, and PCR coupled with mass spectroscopy, are gaining high recognition for identifying and characterizing various pathogens and analysing multiple samples in a single runtime. These factors have increased technology adoption, boosting the European clinical microbiology market size. Many healthcare systems, such as hospitals, clinics, research institutes, and pharmaceutical companies, adopt these techniques to improve diagnostic services. Pathogen-specific diagnostic kits are gaining traction due to early diagnosis in less time by avoiding all the traditional tests for one pathogen. Microbiological testing is utilized for quality assurance for food and beverage products and cosmetic products. 

The growing prevalence of pathogen-based diseases in Europe is further fuelling the growth rate of the European market. Countless pathogens are present around us, and we are exposed to numerous pathogens that are not harmful; only specific pathogens are harmful. Abundant new diseases have been marked in recent years due to pathogens requiring diagnosis and treatment. The increasing number of pathogens species makes end-users focus on innovative and technologically advanced molecular diagnostic techniques. Research laboratories and pharmaceutical companies focus on developing innovative treatment methods with diagnostic patterns. The European government is taking initiatives to develop advanced molecular diagnostic techniques. Specific pathogen diagnostic kits help reduce the time for diagnosis with rapid results, and multiple samples can be tested at a time. 

The increasing technology advancements in the healthcare systems in Europe will create opportunities in the market. Adopting advanced technology will move the healthcare systems toward digital transformation. The increasing government investments in the healthcare infrastructure are expected to create lucrative opportunities for the European clinical microbiology market. With the increasing investments in R&D by the manufacturers, microbiology testing will experience various possibilities by increasing the market revenue.

The clinical microbiology market is limited due to errors in the testing stages. Even one early-stage mistake leads to an overlap of the complete results. The manual data import should avoid overlapping results, such as incorrect identification. The procedures must be done in aseptic areas to avoid contamination, and the microbiologist must be careful with the surroundings. Another factor hampering the European clinical microbiology was the limited reimbursement policies for the testing procedures. The government considers only a few testing procedures under reimbursement, limiting the preference for microbiology testing among patients and healthcare professionals. National Standardization reimbursements need to include some regions affecting the regional market.

The major challenge the European microbiology testing faced was the barriers situated during operational procedures. The samples collected by the labs need to be transported safely with specific temperature requirements and standardized sampling procedures for getting accurate and correct diagnostic results of patients. Patient samples are taken from saliva, semen, tissue, blood, and urine; these have limited the use of automated instruments that directly diagnose common pathogens such as Plasmodium, Staphylococcus, and E. coli.

Impact of COVID-19 on the Europe microbiology testing market:

The COVID-19 pandemic had a positive impact on clinical microbiology as this methodology helped in diagnosing the coronavirus. Advanced molecular techniques, real-time PCR, and isothermal amplification are the standard methods for coronavirus diagnosis. An accurate diagnosis helps better understand the pathogen and the idea of treatment. The nucleic acid amplification method used in microbiology testing had a sensitivity that prevented them from differentiating the dead organisms. Molecular testing was essential to monitor and know the progression of the pandemic. 

This research report on the Europe microbiology testing/clinical microbiology market has been segmented and sub-segmented into the following categories:

By Microbiology Application:

• Pharmaceutical
• Clinical
• Manufacturing
• Energy

By Clinical Application:

• Respiratory Diseases
• STD
• UTI

By Product:

• instruments
• Analyzers
• Consumables

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

European region ranked second in the global microbiology testing due to its advanced healthcare systems. Germany held the dominant share in the European market revenue due to its technological advancements and increasing government investments in developing healthcare infrastructure. Many small clinical laboratories lack the required knowledge of molecular technologies that can use simple and modified, less expensive labor-intensive polymerase chain reaction methods (PCR), accelerating the market growth in this region. Microbiology testing was necessary to know the correct treatment method with effective measures, which played a crucial role in the eradication of the recent pandemic.

The UK is one of the most modernized countries; it adopts technological advancements in all fields, including the healthcare system. People are becoming more prone to infectious diseases, requiring an accurate diagnosis for the correct treatment process, raising the market share. France and Italy are expected to have a decent growth rate in the upcoming years, as infections are increasing and microbiology testing is crucial. To ensure the quality of the products in food and beverages, pharmaceuticals, and skin care, microbiology testing was necessary to avoid the harmful effects on humans. Spain is also considered to grow by influencing the European microbiology testing market value in the forecast period.

KEY MARKET PLAYERS:

Danaher Corporation, Becton, Dickinson, and Company, Cepheid Abbott Laboratories Inc., Bio-Rad Laboratories Inc., F. Hoffman-La Roche Ltd. (Switzerland), Alere Inc, Bruker Corporation, and Hologic, Inc. are some of the leading companies in the European microbiology testing/clinical microbiology market.